Schizophrenia and comorbid cannabis use disorders: Brain structure, function and the effect of antipsychotic medications
Machielsen, Marise

Citation for published version (APA):
Appendix

References


Assies J, Lieverse R, Vreken P, Wanders RJ, Dingemans PM, Linszen DH (2001). Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. *Biological psychiatry* 49, 510-522


Bacon AK, Ham LS (2010). Attention to social threat as a vulnerability to the development of comorbid social anxiety disorder and alcohol use disorders: an avoidance-coping cognitive model. *Addictive Behaviors* 35, 925-939


Buhler M, Vollstadt-Klein S, Kobiella A, Budde H, Reed LJ, Braus DF, Buchel C, Smolka MN (2010). Nicotine dependence is characterized by disordered reward processing in a network driving motivation. *Biological psychiatry* 67, 745-752


Combs DR, Advokat C (2000). Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia. *Schizophrenia research* 46, 129-137


Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. 
*Psychological medicine* **42**, 1903-1911


Franken IH, Hendriksa VM, van den Brink W (2002). Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addictive Behaviors 27, 675-685


Gonzalez-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibanez B, Haidar MK, Vieta E, Arango C (2011). Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophrenia bulletin 37, 631-639

Goudriaan AE, Oosterlaan J, De Beurs E, Van Den Brink W (2008). The role of self-reported impulsivity and reward sensitivity versus neurocognitive measures of disinhibition and decision-making in the prediction of relapse in pathological gamblers. Psychological medicine 38, 41-50


Green AI, Zimmet SV, Strous RD, Schildkraut JJ (1999). Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harvard review of psychiatry 6, 287-296


Gupta N, Basu D (2001). Does risperidone reduce concomitant substance abuse in cases of schizophrenia?. Canadian journal of psychiatry 46, 862-863


Jentsch JD, Taylor JR (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology 146, 373-390


Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP (2002). Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. *Schizophrenia research* **58**, 1-10


Lessov-Schlaggar CN, Lepore RL, Kristjansson SD, Schlaggar BL, Barnes KA, Petersen SE, Madden PA, Heath AC, Barch DM (2013). Functional neuroimaging study in identical twin pairs discordant for regular cigarette smoking. Addiction Biology 18, 98-108

Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM (2012). Maintenance treatment with atipypical drugs for schizophrenia. Cochrane database of systematic reviews (Online) 5, CD008016


Luijtjen M, Van Meel CS, Franken IHA (2011b). Diminished error processing in smokers during smoking cue exposure. Pharmacology Biochemistry and Behavior 97, 514-520

Luijtjen M, Veltman DJ, Hester R, Smits M, Pepplinkhuizen L, Franken IH (2012). Brain activation associated with attentional bias in smokers is modulated by a dopamine antagonist. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 37, 2772-2779


Lysaker P, Bell M, Beam-Goulet J, Milstein R (1994). Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. The Journal of nervous and mental disease 182, 109-112

Machielsen M, Beduin AS, Dekker N, Genetic Risk and Outcome of Psychosis (GROUP) investigators (2012). Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. Journal of psychopharmacology 26, 189-195


Machielsen MW, de Haan L. (2009). Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. Psychopharmacology bulletin 42, 40-52


McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry 59, 921.


Meltzer HY (2012). Clozapine: balancing safety with superior antipsychotic efficacy. Clinical schizophrenia & related psychoses 6, 134-144


Olabarriaga SD, Glatard T, de Boer PT (2010). A virtual laboratory for medical image analysis. IEEE transactions on information technology in biomedicine 14, 979-985


Palaniyappan L, Liddle PF (2012). Differential effects of surface area, gyration and cortical thickness on voxel based morphometric deficits in schizophrenia. Neuroimage 60, 693-699


Peters BD, Blaas J, de Haan L (2010). Diffusion tensor imaging in the early phase of schizophrenia: What have we learned?. Journal of psychiatric research 44, 993-1004


Potenza MN (2006). Should addictive disorders include non-substance-related conditions?. *Addiction* **101** Suppl 1, 142-151


Stroop JR (1935). Studies of interference in serial verbal reactions


TENALEA I. Project.ALEA Randomisation Software (Version 2.2)[Computer Software]. Amsterdam: Netherlands Cancer Institute, 2006


van Holst RJ, Veltman DJ, Buchel C, van den Brink W, Goudriaan AE (2012). Distorted expectancy coding in problem gambling: is the addictive in the anticipation?. *Biological psychiatry* **71**, 741-748

Van Nimwegen LJ, De Haan L, Van Beveren NJ, Van Der Helm M, Van Den Brink W, Linszen D (2008). Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with...
schizophrenia or related disorders: a double-blind randomized controlled trial. *Canadian journal of psychiatry* **53**, 400-405


